Navigation Links
Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
Date:5/22/2013

SAN DIEGO, May 22, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 31 through June 4, 2013, at McCormick Place in Chicago.

Information about the abstracts, including presentation time and location, is listed below. Abstracts can be viewed online at http://abstracts2.asco.org/. Abstract No:
7023Title:Efficacy and Safety of Quizartinib (AC220) in Patients Aged > / = 70 Years with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (AML)Presenter:Alexander Perl, M.D. (University of Pennsylvania)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7012Title:High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation (HSCT) with Quizartinib (AC220) in Patients with FLT3 ITD Positive or Negative Relapsed/Refractory AML After Second Line Chemotherapy or Previous Bone Marrow TransplantPresenter:Jorge Cortes, M.D. (MD Anderson Cancer Center, University of Texas)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7021Title:Quizartinib (AC220) Produces High Response Rates and Long Term Survival in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid LeukemiaPresenter:Giovanni Martinelli, M.D., Ph.D. (University of Bologna School of Medicine)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406 

About QuizartinibQuizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About Ambit BiosciencesAmbit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future therapeutic and commercial potential of Ambit's lead drug candidate and pipeline, business plans, technologies and intellectual property. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts: 
Ian Stone or David Schull (Media) 
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com 
david.schull@russopartnersllc.com

 

 


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
2. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
3. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
6. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
10. Neurocrine Biosciences Reports First Quarter 2012 Results
11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of certain ... failure code.     ... PART NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to any ...
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/14/2017)... N.C. , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away ... reality platform is described by Forbes as "entering the ... American Medical Association as teaching "empathy to medical professionals ... the startup was recently named a finalist for the ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... Gainesville, VA (PRWEB) , ... June 28, 2017 ... ... asset protection assistance and financial consultations to communities in northern Virginia and DC, ... Center to help provide for patients with Alzheimer’s and other disorders that lead ...
(Date:6/27/2017)... Zurich, Switzerland (PRWEB) , ... June 27, 2017 , ... ... crowd to manage token assets on the Ethereum blockchain, has released their technical ... but until now, there has been little systematic approach for determining which offerings will ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th ... to reach a staggering $6.81 billion by the year 2024 according to a new ... faster rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
Breaking Medicine News(10 mins):